Pricing Log in Create free account
Saturday 17 October 2026 Export ABBV’s income statement to Excel — free account

AbbVie Inc.

ABBV Healthcare Drug Manufacturers General

AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 290.4%, free cash flow fell 36.2% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.

285.42 2.02 +0.71%
Market cap
$500.8B
P/E
80.6×
Fwd P/E
27.8×
Dividend yield
2.42%
F-score
8/9
Altman Z
2.31
Beneish M
−2.86
Dividend safety
44/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

AbbVie Inc. (ABBV) Price to free cash flow

Alert me on Price to free cash flow

As of 16 October 2026, AbbVie Inc. (ABBV) trades at a price to free cash flow of 27.7×. Over the past ten years it has ranged from 7.3× (August 2019) to 36.7× (January 2015); the current reading is higher than 97% of that period. That is above the Drug Manufacturers General industry median of 16.5× and above the Healthcare sector median of 20.2×.

Price to free cash flow, daily

Embed this chart

Annual newest first

Period Price to free cash flow Change
FY2025 22.7× 28.70%
FY2024 17.6× 37.64%
FY2023 12.8× 7.99%
FY2022 11.9× 8.82%
FY2021 10.9× 2.44%
FY2020 10.6× 3.62%
FY2019 10.3× (7.58%)
FY2018 11.1× (33.30%)
FY2017 16.7× 7.96%
FY2016 15.4× 12.22%

Quarterly newest first

Period Price to free cash flow Change
Jun 2026 24.4× 26.88%
Mar 2026 19.3× (15.08%)
Dec 2025 22.7× 9.03%
Sep 2025 20.8× 15.65%
42 more quarters

Against its own ten years

Low 7.3× High 36.7×
Ten-year median 13.3×
Current reading's percentile 97

Price to free cash flow against peers

Company Price to free cash flow
GILD Gilead Sciences, Inc. compare 15.0×
PFE Pfizer Inc. compare 16.5×
NVS Novartis AG compare 18.9×
MRK Merck & Co., Inc. compare 22.4×
AMGN Amgen Inc. compare 24.0×
JNJ Johnson & Johnson compare 27.1×
ABBV AbbVie Inc. 27.7×
AZN AstraZeneca PLC compare 40.9×
LLY Eli Lilly and Company compare 55.0×
Drug Manufacturers General industry median 16.5×
Healthcare sector median 20.2×
Market median 14.2×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

More on ABBV